Dry-eye expert Allergan bets $125M on Oculeve and its new implant approach

Allergan ($AGN) is adding to its dry-eye lineup with a new purchase agreement. The company has bet $125 million on a new approach to the disease, picking up Oculeve and lead candidate OD-01--a nerve-stimulating implant placed in the nose. More from FierceBiotech

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

Roche Canada's new innovation challenge to fight COVID-19 has an April 10 deadline and promises up to $100,000 to fund development.

Merck, Eli Lilly and Pfizer have launched or expanded volunteer programs to dedicate medical workers to the COVID-19 effort.